ArticleMolecular imaging and biology2022
EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.
Article in Molecular imaging and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Deciphering riddles in molecular subtyping of bladder cancer.Asian journal of urology · 2025Review
- Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.Cancers · 2025Review
- Immuno-PET Imaging of EGFR withMolecular pharmaceutics · 2024Article
- Review
- Review
- PET Imaging in Bladder Cancer: An Update and Future Direction.Pharmaceuticals (Basel, Switzerland) · 2023Review
- ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeImmuno-positron emission tomography (immunoPET) combines the specificity of an antibody with the sensitivity of PET to image dysregulated pathways in cancer. This study examines the performance of immunoPET using the radioimmunoconjugate [ PROCEDURES: Expression and quantification of EGFR receptors were confirmed in four different BCa cell lines. Binding assays validated [
results[
conclusionThe preclinical data presents a proof of concept for utilizing EGFR-targeted immunoPET to image BCa with altered EGFR protein levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.